Stockreport

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

eFFECTOR Therapeutics, Inc.  (EFTR) 
PDF SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (“STR [Read more]